Findings

What do systematic reviews say?

8 questions · 8 findings · 7 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 37.5%GRADE not reported 0 · 0%Very low 1 · 12.5%Low 1 · 12.5%Moderate 2 · 25%High 1 · 12.5%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Related · question page
- Beta‐2 agonists vs placebo · Participant‐reported outcomes: quality of life (measured by CFQ‐R)
  Long‐acting inhaled bronchodilators for cystic fibrosis 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
Related · question page
- Short‐acting inhaled beta‐2 agonists vs placebo · Quality of life Â
  Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
Related · question page
- Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists · Quality of life Â
  Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
Related · question page
- Tiotropium + LABA/ICS combination vs tiotropium · Quality of life up to 6 months (SGRQ)
  Combination inhaled steroid and long‐acting beta₂‐agonist in addition to tiotropium versus tiotropium or combination… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 4 participants
  Low
Related · question page
- Once‐daily ICS/LABA combined inhalers vs once‐daily LAMA · Quality of life
  Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 779 participants
  Very low

Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists

Quality of life Â · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐acting inhaled beta‐2 agonists vs placebo

Quality of life Â · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

LABA/LAMA vs LABA plus inhaled corticosteroid (ICS)

Change in SGRQ total score · stable COPD

Long‐acting muscarinic antagonist (LAMA) plus long‐acting… showed no clear difference in quality of life as measured by SGRQ total score change from baseline… compared with LABA plus inhaled corticosteroid (ICS) (moderate certainty).

1 finding from 1 review

Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid… 2023 · Cochrane Headline outcomes only
no estimate extracted
9 studies · 14437 participants
Moderate

Beta‐2 agonists vs placebo

Participant‐reported outcomes: quality of life (measured by CFQ‐R) · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Long‐acting inhaled bronchodilators for cystic fibrosis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Once‐daily ICS/LABA combined inhalers vs once‐daily LAMA

Quality of life · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic… 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 779 participants
Very low

Intervention not reported

Quality of life (AQLQ) · adults with asthma

1 finding from 1 review

Long‐acting muscarinic antagonists (LAMA) added to combination long‐acting beta₂‐agonists and inhaled corticosteroids… 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 907 participants
High

Tiotropium + LABA/ICS combination vs tiotropium

Quality of life St George's Respiratory Questionnaire (SGRQ) score · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Combination inhaled steroid and long‐acting beta₂‐agonist in addition to tiotropium versus tiotropium or combination… 2016 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 4 participants
Low

Stopping LABA vs continuing use of LABA+ICS

Asthma‐related quality of life (MCID) · adults with asthma well controlled on LABA and ICS

1 finding from 1 review

Stopping long‐acting beta₂‐agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 359 participants
Moderate